1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Data For Two HER2-Positive Breast Cancer Drugs Impress, Including On Overall Survival

 
• By Jessica Merrill

AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.

SC1912_Target_1423512623_1200.jpg
Two new breast cancer drugs hit their target in pivotal trials • Source: Shutterstock

Metastatic HER2-positive breast cancer patients who have run out of treatment options soon could have two new therapies that have shown progression-free survival (PFS) and overall survival (OS) benefits in clinical trials. However, it's still unclear how the launch of two new drugs for the challenging patient population might play out in the commercial market and how the two drugs could be sequenced.

Partners AstraZeneca PLC and Daiichi Sankyo Co. Ltd. presented data on the antibody-drug conjugate (ADC) trastuzumab deruxtecan (DS-8201) and Seattle Genetics Inc. presented data on the tyrosine...

More from Anticancer

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

More from Therapy Areas